Travere Therapeutics Inc. has announced the issuance of inducement equity grants to 17 new employees, as approved by the Compensation Committee of its Board of Directors on July 10, 2025. These grants consist of restricted stock units (RSUs) covering a total of 121,700 shares of the company's common stock. The RSUs, though issued outside of Travere's 2018 Equity Incentive Plan, adhere to its terms and were granted under Nasdaq Listing Rule 5635(c)(4) as part of the company's strategy to attract new talent. The RSUs will vest over a four-year period, with 25% of the shares vesting on each anniversary of the grant date, contingent upon the continued service of the employees with the company through the vesting dates.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250711315784) on July 11, 2025, and is solely responsible for the information contained therein.